Author:
Znojek P,Willmore E,Curtin N J
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Barrows LR, Holden JA, Anderson M, D’Arpa P (1998) The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication. Mutat Res 408: 103–110.
2. Bowman KJ, Newell DR, Calvert AH, Curtin NJ (2001) Differential effects of the poly(ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity. Br J Cancer 84: 106–112.
3. Bryant HE, Petermann E, Schultz N, Jemth AS, Loseva O, Issaeva N, Johansson F, Fernandez S, McGlynn P, Helleday T (2009) PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J 28: 2601–2615.
4. Burkle A, Schreiber V, Dantzer F, Oliver FJ, deMurcia G, Menissier-de Murcia J (2000) Biological significance of poly(ADP-ribosylation) reactions: molecular and genetic approaches. In: From DNA Damage and Stress Signalling to Cell Death: Poly ADP-Ribosylation Reactions, de Murcia G, Shall S (eds.), pp 80–124 O.U.P: Oxford, UK.
5. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, North M, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang L-Z, Webber SE, Williams KJ, Curtin NJ (2004) Preclinical evaluation of a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, AG14361, with significant anticancer chemo- and radio-sensitization activity. J Natl Cancer Inst 96: 56–67.
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献